Patricia Zúñiga-García

Patricia Zúñiga-García

Auto-generated profile, based on publicly available information

Patricia Zúñiga-García

CIC bioGUNE, Bizkaia Technology Park, Derio, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
VTVeronica Torrano
Veronica Torrano
LVLorea Valcarcel-Jimenez
Lorea Valcarcel-Jimenez
ACAna Rosa Cortazar
Ana Rosa Cortazar
XLXiaojing Liu
Xiaojing Liu
JUJelena Urosevic
Jelena Urosevic
ACArkaitz Carracedo
Arkaitz Carracedo
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.

28 June 2017 in Nature
Verified
Journal Article
Open access
PDF file
AZAmaia Zabala-Letona
Amaia Zabala-Letona
AAAmaia Arruabarrena-Aristorena
Amaia Arruabarrena-Aristorena
NMNatalia Martín-Martín
Natalia Martín-Martín
SFSonia Fernandez-Ruiz
Sonia Fernandez-Ruiz
JSJames D. Sutherland
James D. Sutherland
ACArkaitz Carracedo
Arkaitz Carracedo
MTOR complex 1 signalling regulates polyamine metabolism and thereby promotes tumorigenesis, through regulation of the stability of a key enzyme, AMD1. The mTOR pathway regulates multiple metabolic pathways in cancers but knowledge of how oncogenic signals regulate polyamine production, which is important in spreading cancer cells, is limited. Arkaitz Carracedo and colleagues add to the existing knowledge. Using a mixture of metabolic analysis techniques, they show that mTOR signalling regulates polyamine metabolism and thereby promotes tumorigenesis through regulation of the stability of a key enzyme, AMD1. They validated this pathway in mouse and human cancer specimens and found that ADM1 is upregulated in prostate cancer specimens with activated mTORC1. This adds to the complexity of cancer cell metabolism and offers new therapeutic avenues. Activation of the PTEN–PI3K–mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.

7 May 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
MCMarc Clos-Garcia
Marc Clos-Garcia
ALAna Loizaga‐Iriarte
Ana Loizaga‐Iriarte
PZPatricia Zuñiga‐Garcia
Patricia Zuñiga‐Garcia
PSPilar Sánchez‐Mosquera
Pilar Sánchez‐Mosquera
ACAna Rosa Cortazar
Ana Rosa Cortazar
JFJuan M Falcon-Perez
Juan M Falcon-Perez
Urine contains extracellular vesicles (EVs) that concentrate molecules and protect them from degradation. Thus, isolation and characterisation of urinary EVs could increase the efficiency of biomarker discovery. We have previously identified proteins and RNAs with differential abundance in urinary EVs from prostate cancer (PCa) patients compared to benign prostate hyperplasia (BPH). Here, we focused on the analysis of the metabolites contained in urinary EVs collected from patients with PCa and BPH. Targeted metabolomics analysis of EVs was performed by ultra‐high‐performance liquid chromatography–mass spectrometry. The correlation between metabolites and clinical parameters was studied, and metabolites with differential abundance in PCa urinary EVs were detected and mapped into cellular pathways. We detected 248 metabolites belonging to different chemical families including amino acids and various lipid species. Among these metabolites, 76 exhibited significant differential abundance between PCa and BPH. Interestingly, urine EVs recapitulated many of the metabolic alterations reported in PCa, including phosphathidylcholines, acyl carnitines, citrate and kynurenine. Importantly, we found elevated levels of the steroid hormone, 3beta‐hydroxyandros‐5‐en‐17‐one‐3‐sulphate (dehydroepiandrosterone sulphate) in PCa urinary EVs, in line with the potential elevation of androgen synthesis in this type of cancer. This work supports urinary EVs as a non‐invasive source to infer metabolic changes in PCa.

1 January 2016 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
FRFelix Royo
Felix Royo
PZPatricia Zuñiga‐Garcia
Patricia Zuñiga‐Garcia
PSPilar Sanchez‐Mosquera
Pilar Sanchez‐Mosquera
AEAinara Egia
Ainara Egia
APAmparo Perez
Amparo Perez
JFJuan M Falcon-Perez
Juan M Falcon-Perez
Urine sample analysis is irreplaceable as a non‐invasive method for disease diagnosis and follow‐up. However, in urine samples, non‐degraded protein and RNA may be only found in urinary extracellular vesicles (uEVs). In recent years, various methods of uEV enrichment using low volumes of urine and unsophisticated equipment have been developed, with variable success. We compared the results of the differential ultracentrifugation procedure with 4 of these methods. The methods tested were a lectin‐based purification, Exoquick (System Biosciences), Total Exosome Isolation from Invitrogen and an in‐house modified procedure employing the Exosomal RNA Kit from Norgen Biotek Corp. The analysis of selected gene transcripts and protein markers of extracellular vesicles (EVs) revealed that each method isolates a different mixture of uEV protein markers. In our conditions, the extraction with Norgen's reagent achieved the best performance in terms of gene transcript and protein detection and reproducibility. By using this method, we were able to detect alterations of EVs protein markers in urine samples from prostate cancer adenoma patients. Taken together, our results show that the isolation of uEVs is feasible from small volumes of urine and avoiding ultracentrifugation, making easier the analysis in a clinical facility. However, caution should be taken in the selection of the enrichment method since they have a differential affinity for protein uEVs markers and by extension for different subpopulation of EVs.

29 August 2014 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
MSM Salazar
M Salazar
MLMar Lorente
Mar Lorente
EGE García-Taboada
E García-Taboada
EPEduardo Pérez-Gómez
Eduardo Pérez-Gómez
DDD Dávila
D Dávila
GDGuillermo Velasco Díez
Guillermo Velasco Díez
Tribbles pseudokinase-3 (TRIB3) has been proposed to act as an inhibitor of AKT although the precise molecular basis of this activity and whether the loss of TRIB3 contributes to cancer initiation and progression remain to be clarified. In this study, by using a wide array of in vitro and in vivo approaches, including a Trib3 knockout mouse, we demonstrate that TRIB3 has a tumor-suppressing role. We also find that the mechanism by which TRIB3 loss enhances tumorigenesis relies on the dysregulation of the phosphorylation of AKT by the mTORC2 complex, which leads to an enhanced phosphorylation of AKT on Ser473 and the subsequent hyperphosphorylation and inactivation of the transcription factor FOXO3. These observations support the notion that loss of TRIB3 is associated with a more aggressive phenotype in various types of tumors by enhancing the activity of the mTORC2/AKT/FOXO axis.

12 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FRFelix Royo
Felix Royo
PZPatricia Zuñiga-Garcia
Patricia Zuñiga-Garcia
VTVerónica Torrano
Verónica Torrano
ALAna Loizaga
Ana Loizaga
PSPilar Sanchez-Mosquera
Pilar Sanchez-Mosquera
ACArkaitz Carracedo
Arkaitz Carracedo
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer